Philips launches cognitive assessment platformJanuary 6, 2020
Royal Philips has introduced IntelliSpace Cognition platform to assess cognition in patients with debilitating neurological conditions
IntelliSpace Cognition automates and enhances well-established neuropsychological tests, offering new insights for clinicians.
It provides direct access to detailed information about a patient’s cognition while also providing quantitative longitudinal data to aid in assessing disease progression and treatment efficacy.
A crucial care pathway for neurologists is to refer patients to neuropsychologists whose expertise in assessing cognitive issues provides important information for treatment. While treatment may be limited for some neurodegenerative diseases, it is vital to act as early as possible to establish an appropriate care plan or treatment protocol.
A rapid and reliable method for neurologists to better assess cognition and select those that would benefit from seeing a neuropsychologist would alleviate pressure on this part of the healthcare system.